from concepts to biomarkers

& innovations in precision medicine

17 research teams,

9 platforms, 3 hosted biotechs

our state-of-the-art tools,

for cancer research

in the heart of a campus dedicated to applied cancer research...

...and Montpellier,

a city historically linked to medical research and teaching

the IRCM research teams
the IRCM research teams

L'Institut de Recherche en Cancérologie de Montpellier :
«Together, let's push the boundaries»


seminaire mabimprove

Valérie Attuil-Audenis

Ph.D, Responsable département produits, Covalab

“Highly-loaded hydrophilic ADC drug linker platform”

Contact IRCM : Thierry Chardès

En savoir plus

22 & 23 june 2020 : 8th Antibody Industrial Symposium « Multispecific Antibodies, Ab-like Molecules and Adoptive Cell Therapy for Fighting Diseases »At Montpellier, Le CorumAs leaders of the organizing committee and members of the scientific committee, IRCM scientists are proud to share with you the next AIS2020 programme. This symposium will present new scientific advances and perspectives on multispecies antibodies, immunocytokines and CAR-T cells. The objectives are to foster interactions between academic researchers, clinicians, physicians and pharmacists, and industrialists in the field of therapeutic antibodies and immunotherapy. Organization : LabEx MAbImprove & MabDesignInstitutional support: University of Montpellier, MUSE, Region OccitanieMore :  
En savoir plus

Poste à pourvoir à l'IRCM

Postdoctoral Position in Modeling of the Tumor MicroenvironmentDate limite de candidature : 31/12/2019The Colinge Laboratory Cancer Bioinformatics and Systems Biology at IRCM (Cancer Research Institute of Montpellier) is looking for a talented postdoctoral fellow to work on the evolution of the tumor microenvironment (TME) in response to therapy. This computational work will build upon on-going developments conducted in the lab to infer cellular interactions taking place in the TME. Both single-cell and bulk transcriptomics configurations will be considered. A significant part of the research will relate to lung adenocarcinoma and involve a consortium of expert laboratories in lung cancer and mouse models thereof, animal computer tomography, and 3D imaging. The postdoc position is funded for three years; a 1-year contract will be offered first and extended for another two years based on performance. Preferred qualifications are a bioinformatics Ph.D. with solid computational skills or a mathematics, physics, or computer science Ph.D. with strong interests in life science applications. Interested applicants should e-mail their CV, a letter of motivation, and the names and e-mails of 2 references to Prof Jacques Colinge (at Applications will be studied immediately. Selected publicationsAlame et al., The molecular landscape and microenvironment of salivary duct carcinoma reveal new therapeutic opportunities, bioRxiv, 2019Lehmann et al., In Vivo Large-Scale Mapping Of Protein Turnover In The Human Cerebrospinal Fluid, bioRxiv, 2019Blomen et al. Gene essentiality and synthetic lethality in haploid human cells. Science, 2015Pichlmair et al. Viral immune modulators perturb the human molecular network by common and unique strategies, Nature, 2012Stukalov et al. Deconvolution of targeted protein-protein interaction maps. J Proteome Res, 2012  
En savoir plus

Inauguration du CyTOF/HYPERION

L’Institut de Recherche en Cancérologie de Montpellier a inauguré, le 18 septembre 2019, une plateforme d’imagerie par cytométrie de masse basée sur la technologie CyTOF/Hyperion permettant, pour la première fois en France, de cartographier le microenvironnement cellulaire et l’hétérogénéité tumorale. Cette technologie, unique en France, est porteuse de nouveaux espoirs pour les patients. Elle devrait permettre, à l’heure où l’immunothérapie a des effets cliniques spectaculaires, y compris chez des patients en échappement thérapeutique, d’approfondir la connaissance sur ces nouvelles thérapies anticancéreuses.    Communiqué de presse Inauguration CyTOF IRCM
En savoir plus

the word of the director

"Together, let's push the boundaries."

«In just 20 years, the Institut de Recherche en Cancérologie de Montpellier (IRCM U1194) has raised its research to the highest international level in the field of fundamental and applied oncology, research carried out in close collaboration with the clinical departments of the Centre de Lutte Contre le Cancer de Montpellier (ICM: Institut du Cancer de Montpellier), and industrial partners. Jointly operated by Inserm, ICM and the University of Montpellier, the IRCM now brings together more than 200 people, researchers, clinicians, technicians and students, organised into 17 research teams supported by efficient technical platforms and support services. In an extremely competitive and rapidly evolving field of research, our greatest challenge is to stay one step ahead, seek excellence, accelerate innovation and transfer to the patient to ultimately help overcome the countless different forms of cancer.Together, let's push the boundaries.»

Claude Sardet, Director of the IRCM

the word of the director


Bousquet Mur E, Bernardo S, Papon L, Mancini M, Fabbrizio E, Goussard M, Ferrer I, Giry A, Quantin X, Pujol J-L, Calvayrac O, Moll H, Glasson Y, Pirot N, Turtoi A, Cañamero M, Wong K-K, Yarden Y, Casanova E, Soria J-C, Colinge J, Siebel C, Favre G, Paz-Ares L, Maraver A Notch inhibition overcomes resistance to Tyrosine Kinase Inhibitors in EGFR-driven lung adenocarcinoma. J. Clin. Invest.. Oct 31, 2019. doi:10.1172/JCI126896

Combes E, Andrade A, Tosi D, Michaud H-A, Coquel F, Desigaud D, Jarlier M, Coquelle A, Pasero P, Bonnefoy N, Martineau P, Del Rio M, Beijersbergen R, Vezzio-Vie N Inhibition of Ataxia-Telangiectasia Mutated and RAD3-related (ATR) overcomes oxaliplatin resistance and promotes anti-tumor immunity in colorectal cancer. Cancer Res.. Apr 15, 2019. doi:10.1158/0008-5472.CAN-18-2807

Ashraf Y, Mansouri H, Laurent-Matha V, Alcaraz L, Roger P, Guiu S, Derocq D, Robin G, Michaud H-A, Jarlier M, Pugnière M, Robert B, Puel A, Martin L, Landomiel F, Bourquard T, Achour O, Fruitier-Arnaudin I, Pichard A, Deshayes E, Turtoi A, Poupon A, Boissière-Michot F, Pirot N, Bernex F, Jacot W, du Manoir S, Theillet C, Pouget J-P, Navarro-Teulon I, Bonnefoy N, Pèlegrin A, Chardès T, Martineau P, Liaudet-Coopman E Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies. J Immunother Cancer. 2019;7(1):29. doi:10.1186/s40425-019-0498-z

Ladjohounlou R, Lozza C, Pichard A, Constanzo J, Karam J, Le Fur P, Deshayes E, Boudousq V, Paillas S, Busson M, Le Blay M, Jarlier M, Marcatili S, Bardiès M, Bruchertseifer F, Morgenstern A, Torgue J, Navarro-Teulon I, Pouget J-P Drugs that modify cholesterol metabolism alter the p38/JNK-mediated targeted and non-targeted response to alpha and Auger radioimmunotherapy. Clin. Cancer Res.. May 06, 2019. doi:10.1158/1078-0432.CCR-18-3295

Perrot I, Michaud H-A, Giraudon-Paoli M, Augier S, Docquier A, Gros L, Courtois R, Jecko D, Becquart O, Rispaud-Blanc H, Gauthier L, Rossi B, Chanteux S, Gourdin N, Amigues B, Roussel A, Bensussan A, Eliaou J-F, Bastid J, Romagné F, Morel Y, Narni-Mancinelli E, Vivier E, Paturel C, Bonnefoy N Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies. Cell Rep. 2019;27(8):2411-2425.e9. doi:10.1016/j.celrep.2019.04.091

Forest E, Logeay R, Géminard C, Kantar D, Frayssinoux F, Heron-Milhavet L, Djiane A The apical scaffold big bang binds to spectrins and regulates the growth of Drosophila melanogaster wing discs. J. Cell Biol.. 2018;217(3):1047-1062. doi:10.1083/jcb.201705107

Arena G, Cissé M, Pyrdziak S, Chatre L, Riscal R, Fuentes M, Arnold J, Kastner M, Gayte L, Bertrand-Gaday C, Nay K, Angebault-Prouteau C, Murray K, Chabi B, Koechlin-Ramonatxo C, Orsetti B, Vincent C, Marine J-C, Etienne-Manneville S, Bernex F, Lombès A, Cameron C, Dubouchaud H, Ricchetti M, Linares L, Le Cam L Mitochondrial MDM2 Regulates Respiratory Complex I Activity Independently of p53. Mol. Cell. 2018;69(4):594-609.e8. doi:10.1016/j.molcel.2018.01.023

Leconet W, Chentouf M, du Manoir S, Chevalier C, Sirvent A, Aït-Arsa I, Busson M, Jarlier M, Radosevic-Robin N, Theillet C, Chalbos D, Pasquet J-M, Pèlegrin A, Larbouret C, Robert B Therapeutic Activity of Anti-AXL Antibody against Triple-Negative Breast Cancer Patient-Derived Xenografts and Metastasis. Clin. Cancer Res.. 2017;23(11):2806-2816. doi:10.1158/1078-0432.CCR-16-1316

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés